Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 180

1.

Effects of Gastrointestinal-Type Chemotherapy in Women With Ovarian Mucinous Carcinoma.

Kurnit KC, Sinno AK, Fellman BM, Varghese A, Stone R, Sood AK, Gershenson DM, Schmeler KM, Malpica A, Fader AN, Frumovitz M.

Obstet Gynecol. 2019 Dec;134(6):1253-1259. doi: 10.1097/AOG.0000000000003579.

PMID:
31764736
2.

Effects of Gastrointestinal-Type Chemotherapy in Women With Ovarian Mucinous Carcinoma.

Kurnit KC, Sinno AK, Fellman BM, Varghese A, Stone R, Sood AK, Gershenson DM, Schmeler KM, Malpica A, Fader AN, Frumovitz M.

Obstet Gynecol. 2019 Nov 4. doi: 10.1097/AOG.0000000000003579. [Epub ahead of print]

PMID:
31698370
3.

Systematic Approach to Selecting and Preparing a Medical Power of Attorney in the Gynecologic Oncology Center.

Zhukovsky DS, Soliman PT, Mathew B, Mills S, Bodurka D, Frumovitz M, Meyer LA, Westin S, Nowitz M, Archie L, Fenton S, Lang K, Williams JL, Boving V, Bruera E.

J Oncol Pract. 2019 Oct 15:JOP1900109. doi: 10.1200/JOP.19.00109. [Epub ahead of print]

PMID:
31613720
4.

Incidence of adverse events in minimally invasive versus open radical hysterectomy in early cervical cancer: Results of a randomized controlled trial.

Obermair A, Asher R, Pareja R, Frumovitz M, Lopez A, Moretti-Marques R, Rendon G, Ribeiro R, Tsunoda A, Behan V, Buda A, Bernadini MQ, Zhao H, Vieira M, Walker J, Spirtos NM, Yao S, Chetty N, Zhu T, Isla D, Tamura M, Nicklin J, Robledo KP, Gebski V, Coleman RL, Salvo G, Ramirez PT.

Am J Obstet Gynecol. 2019 Oct 3. pii: S0002-9378(19)31165-2. doi: 10.1016/j.ajog.2019.09.036. [Epub ahead of print]

PMID:
31586602
5.

Updates and management algorithm for neuroendocrine tumors of the uterine cervix.

Salvo G, Gonzalez Martin A, Gonzales NR, Frumovitz M.

Int J Gynecol Cancer. 2019 Jul;29(6):986-995. doi: 10.1136/ijgc-2019-000504.

PMID:
31263021
6.

Preoperative PET/CT does not accurately detect extrauterine disease in patients with newly diagnosed high-risk endometrial cancer: A prospective study.

Stewart KI, Chasen B, Erwin W, Fleming N, Westin SN, Dioun S, Frumovitz M, Ramirez PT, Lu KH, Wong F, Aloia TA, Soliman PT.

Cancer. 2019 Oct 1;125(19):3347-3353. doi: 10.1002/cncr.32329. Epub 2019 Jun 21.

PMID:
31225906
7.

Adaptive responses in a PARP inhibitor window of opportunity trial illustrate limited functional interlesional heterogeneity and potential combination therapy options.

Labrie M, Kim TB, Ju Z, Lee S, Zhao W, Fang Y, Lu Y, Chen K, Ramirez P, Frumovitz M, Meyer L, Fleming ND, Sood AK, Coleman RL, Mills GB, Westin SN.

Oncotarget. 2019 May 28;10(37):3533-3546. doi: 10.18632/oncotarget.26947. eCollection 2019 May 28.

8.

Volumetric assessment of apparent diffusion coefficient predicts outcome following chemoradiation for cervical cancer.

Ho JC, Fang P, Cardenas CE, Mohamed ASR, Fuller CD, Allen PK, Bhosale PR, Frumovitz MM, Jhingran A, Klopp AH.

Radiother Oncol. 2019 Jun;135:58-64. doi: 10.1016/j.radonc.2019.02.012. Epub 2019 Mar 11.

PMID:
31015171
9.

An international, phase III randomized trial in patients with mucinous epithelial ovarian cancer (mEOC/GOG 0241) with long-term follow-up: and experience of conducting a clinical trial in a rare gynecological tumor.

Gore M, Hackshaw A, Brady WE, Penson RT, Zaino R, McCluggage WG, Ganesan R, Wilkinson N, Perren T, Montes A, Summers J, Lord R, Dark G, Rustin G, Mackean M, Reed N, Kehoe S, Frumovitz M, Christensen H, Feeney A, Ledermann J, Gershenson DM.

Gynecol Oncol. 2019 Jun;153(3):541-548. doi: 10.1016/j.ygyno.2019.03.256. Epub 2019 Apr 18.

10.

Reproductive counseling and pregnancy outcomes after radical trachelectomy for early stage cervical cancer.

Shah JS, Jooya ND, Woodard TL, Ramirez PT, Fleming ND, Frumovitz M.

J Gynecol Oncol. 2019 May;30(3):e45. doi: 10.3802/jgo.2019.30.e45.

11.

Tailoring adjuvant treatment in patients with uterine cancer - Authors' reply.

Frumovitz M, Abu-Rustum NR.

Lancet Oncol. 2018 Dec;19(12):e656. doi: 10.1016/S1470-2045(18)30832-5. No abstract available.

PMID:
30507416
12.

Perineural invasion (PNI) in vulvar carcinoma: A review of 421 cases.

Salcedo MP, Sood AK, Dos Reis R, Ramalingam P, Chen C, Frumovitz M, Jhingran A, Pitcher B, Ramirez PT, Schmeler KM.

Gynecol Oncol. 2019 Jan;152(1):101-105. doi: 10.1016/j.ygyno.2018.10.035. Epub 2018 Nov 3.

PMID:
30396690
13.

Minimally Invasive versus Abdominal Radical Hysterectomy for Cervical Cancer.

Ramirez PT, Frumovitz M, Pareja R, Lopez A, Vieira M, Ribeiro R, Buda A, Yan X, Shuzhong Y, Chetty N, Isla D, Tamura M, Zhu T, Robledo KP, Gebski V, Asher R, Behan V, Nicklin JL, Coleman RL, Obermair A.

N Engl J Med. 2018 Nov 15;379(20):1895-1904. doi: 10.1056/NEJMoa1806395. Epub 2018 Oct 31.

PMID:
30380365
14.

PRKRA/PACT Expression Promotes Chemoresistance of Mucinous Ovarian Cancer.

Hisamatsu T, McGuire M, Wu SY, Rupaimoole R, Pradeep S, Bayraktar E, Noh K, Hu W, Hansen JM, Lyons Y, Gharpure KM, Nagaraja AS, Mangala LS, Mitamura T, Rodriguez-Aguayo C, Eun YG, Rose J, Bartholomeusz G, Ivan C, Lee JS, Matsuo K, Frumovitz M, Wong KK, Lopez-Berestein G, Sood AK.

Mol Cancer Ther. 2019 Jan;18(1):162-172. doi: 10.1158/1535-7163.MCT-17-1050. Epub 2018 Oct 10.

PMID:
30305341
15.

Gene Expression Analysis Identifies Novel Targets for Cervical Cancer Therapy.

Roszik J, Ring KL, Wani KM, Lazar AJ, Yemelyanova AV, Soliman PT, Frumovitz M, Jazaeri AA.

Front Immunol. 2018 Sep 19;9:2102. doi: 10.3389/fimmu.2018.02102. eCollection 2018.

16.

A practical guide for the safe implementation of early phase drug development and immunotherapy program in gynecologic oncology practice.

Jazaeri A, Coleman RL, Sood AK, Frumovitz MM, Soliman PT, Shafer A, Cutrera JJ, Klinger M, Sharafi SE, Johnson CAL, Villanueva VF, Hinchcliff EM, Dickens A, Cain KE, Anderson JE, Lu KH, Westin SN.

Gynecol Oncol. 2018 Nov;151(2):374-380. doi: 10.1016/j.ygyno.2018.08.037. Epub 2018 Sep 10. Review.

17.

Near-infrared fluorescence for detection of sentinel lymph nodes in women with cervical and uterine cancers (FILM): a randomised, phase 3, multicentre, non-inferiority trial.

Frumovitz M, Plante M, Lee PS, Sandadi S, Lilja JF, Escobar PF, Gien LT, Urbauer DL, Abu-Rustum NR.

Lancet Oncol. 2018 Oct;19(10):1394-1403. doi: 10.1016/S1470-2045(18)30448-0. Epub 2018 Aug 22.

18.

Impact of Sentinel Node Approach in Gynecologic Cancer on Training Needs.

Kumar A, Wallace SA, Cliby WA, Glaser GE, Mariani A, Leitao MM, Frumovitz M, Langstraat CL.

J Minim Invasive Gynecol. 2019 May - Jun;26(4):727-732. doi: 10.1016/j.jmig.2018.08.006. Epub 2018 Aug 20.

PMID:
30138740
19.

The influence of surgeon volume on outcomes after pelvic exenteration for a gynecologic cancer.

Jalloul RJ, Nick AM, Munsell MF, Westin SN, Ramirez PT, Frumovitz M, Soliman PT.

J Gynecol Oncol. 2018 Sep;29(5):e68. doi: 10.3802/jgo.2018.29.e68. Epub 2018 May 4.

20.

Imaging and staging of neuroendocrine cervical cancer.

Elsherif S, Odisio EGLC, Faria S, Javadi S, Yedururi S, Frumovitz M, Ramalingam P, Bhosale P.

Abdom Radiol (NY). 2018 Dec;43(12):3468-3478. doi: 10.1007/s00261-018-1667-0. Review.

PMID:
29974177
21.

Can MRI help assess aggressiveness of endometrial cancer?

Ahmed M, Al-Khafaji JF, Class CA, Wei W, Ramalingam P, Wakkaa H, Soliman PT, Frumovitz M, Iyer RB, Bhosale PR.

Clin Radiol. 2018 Sep;73(9):833.e11-833.e18. doi: 10.1016/j.crad.2018.05.002. Epub 2018 Jun 9.

PMID:
29895385
22.

Simple trachelectomy with pelvic lymphadenectomy as a viable treatment option in pregnant patients with stage IB1 (≥2 cm) cervical cancer: Bridging the gap to fetal viability.

Salvo G, Frumovitz M, Pareja R, Lee J, Ramirez PT.

Gynecol Oncol. 2018 Jul;150(1):50-55. doi: 10.1016/j.ygyno.2018.05.021. Epub 2018 May 24.

PMID:
29804639
23.

Accuracy of Intraoperative Frozen Section Diagnosis of Borderline Ovarian Tumors by Hospital Type.

Shah JS, Mackelvie M, Gershenson DM, Ramalingam P, Kott MM, Brown J, Gauthier P, Nugent E, Ramondetta LM, Frumovitz M.

J Minim Invasive Gynecol. 2019 Jan;26(1):87-93. doi: 10.1016/j.jmig.2018.04.005. Epub 2018 Apr 19.

PMID:
29680231
24.

Radical Hysterectomy and Age: Outcomes Comparison Based on a Minimally Invasive vs an Open Approach.

Dos Reis R, Andrade CEMC, Frumovitz M, Munsell M, Ramirez PT.

J Minim Invasive Gynecol. 2018 Nov - Dec;25(7):1224-1230. doi: 10.1016/j.jmig.2018.03.002. Epub 2018 Mar 9.

PMID:
29530834
25.

Radical parametrectomy after 'cut-through' hysterectomy in low-risk early-stage cervical cancer: Time to consider this procedure obsolete.

Pareja R, Echeverri L, Rendon G, Munsell M, Gonzalez-Comadran M, Sanabria D, Isla D, Frumovitz M, Ramirez PT.

Gynecol Oncol. 2018 Jun;149(3):520-524. doi: 10.1016/j.ygyno.2018.02.015. Epub 2018 Mar 1.

PMID:
29482838
26.

Effectiveness of definitive radiotherapy for squamous cell carcinoma of the vulva with gross inguinal lymphadenopathy.

Stecklein SR, Frumovitz M, Klopp AH, Gunther JR, Eifel PJ.

Gynecol Oncol. 2018 Mar;148(3):474-479. doi: 10.1016/j.ygyno.2018.01.007. Epub 2018 Jan 12.

PMID:
29336837
27.

Outcomes and patterns of relapse after definitive radiation therapy for oligometastatic cervical cancer.

Ning MS, Ahobila V, Jhingran A, Stecklein SR, Frumovitz M, Schmeler KM, Eifel PJ, Klopp AH.

Gynecol Oncol. 2018 Jan;148(1):132-138. doi: 10.1016/j.ygyno.2017.10.017. Epub 2017 Oct 28.

PMID:
29089122
28.

Sentinel lymph node mapping in minimally invasive surgery: Role of imaging with color-segmented fluorescence (CSF).

Lopez Labrousse MI, Frumovitz M, Guadalupe Patrono M, Ramirez PT.

Gynecol Oncol. 2017 Sep;146(3):676-677. doi: 10.1016/j.ygyno.2017.06.009. Epub 2017 Jun 17.

PMID:
28629611
29.

A prospective validation study of sentinel lymph node mapping for high-risk endometrial cancer.

Soliman PT, Westin SN, Dioun S, Sun CC, Euscher E, Munsell MF, Fleming ND, Levenback C, Frumovitz M, Ramirez PT, Lu KH.

Gynecol Oncol. 2017 Aug;146(2):234-239. doi: 10.1016/j.ygyno.2017.05.016. Epub 2017 May 18.

30.

Potential immunotherapy targets in recurrent cervical cancer.

Ring KL, Yemelyanova AV, Soliman PT, Frumovitz MM, Jazaeri AA.

Gynecol Oncol. 2017 Jun;145(3):462-468. doi: 10.1016/j.ygyno.2017.02.027. Epub 2017 Feb 21.

PMID:
28233576
31.

Sensitivity and negative predictive value for sentinel lymph node biopsy in women with early-stage cervical cancer.

Salvo G, Ramirez PT, Levenback CF, Munsell MF, Euscher ED, Soliman PT, Frumovitz M.

Gynecol Oncol. 2017 Apr;145(1):96-101. doi: 10.1016/j.ygyno.2017.02.005. Epub 2017 Feb 8.

32.

Sentinel Lymph Node Biopsy for Cervical Cancer Patients - What's It Gonna Take?

Frumovitz M.

Gynecol Oncol. 2017 Jan;144(1):3-4. doi: 10.1016/j.ygyno.2016.12.009. No abstract available.

PMID:
28012545
33.

Diffusion-Weighted Magnetic Resonance Imaging as a Predictor of Outcome in Cervical Cancer After Chemoradiation.

Ho JC, Allen PK, Bhosale PR, Rauch GM, Fuller CD, Mohamed AS, Frumovitz M, Jhingran A, Klopp AH.

Int J Radiat Oncol Biol Phys. 2017 Mar 1;97(3):546-553. doi: 10.1016/j.ijrobp.2016.11.015. Epub 2016 Nov 17.

34.

Tumor Thickness and Mitotic Rate Robustly Predict Melanoma-Specific Survival in Patients with Primary Vulvar Melanoma: A Retrospective Review of 100 Cases.

Nagarajan P, Curry JL, Ning J, Piao J, Torres-Cabala CA, Aung PP, Ivan D, Ross MI, Levenback CF, Frumovitz M, Gershenwald JE, Davies MA, Malpica A, Prieto VG, Tetzlaff MT.

Clin Cancer Res. 2017 Apr 15;23(8):2093-2104. doi: 10.1158/1078-0432.CCR-16-2126. Epub 2016 Nov 18.

35.

Combination therapy with topotecan, paclitaxel, and bevacizumab improves progression-free survival in recurrent small cell neuroendocrine carcinoma of the cervix.

Frumovitz M, Munsell MF, Burzawa JK, Byers LA, Ramalingam P, Brown J, Coleman RL.

Gynecol Oncol. 2017 Jan;144(1):46-50. doi: 10.1016/j.ygyno.2016.10.040. Epub 2016 Nov 4.

36.

Utility of indocyanine green (ICG) intra-operative angiography to determine uterine vascular perfusion at the time of radical trachelectomy.

Escobar PF, Ramirez PT, Garcia Ocasio RE, Pareja R, Zimberg S, Sprague M, Frumovitz M.

Gynecol Oncol. 2016 Nov;143(2):357-361. doi: 10.1016/j.ygyno.2016.08.239. Epub 2016 Aug 17.

37.

Quality of life after radical trachelectomy for early-stage cervical cancer: A 5-year prospective evaluation.

Fleming ND, Ramirez PT, Soliman PT, Schmeler KM, Chisholm GB, Nick AM, Westin SN, Frumovitz M.

Gynecol Oncol. 2016 Dec;143(3):596-603. doi: 10.1016/j.ygyno.2016.10.012. Epub 2016 Oct 11.

38.

Patterns of recurrence and survival in neuroendocrine cervical cancer.

Stecklein SR, Jhingran A, Burzawa J, Ramalingam P, Klopp AH, Eifel PJ, Frumovitz M.

Gynecol Oncol. 2016 Dec;143(3):552-557. doi: 10.1016/j.ygyno.2016.09.011. Epub 2016 Sep 16.

39.

Can reduced field-of-view diffusion sequence help assess microsatellite instability in FIGO stage 1 endometrial cancer?

Bhosale P, Ramalingam P, Ma J, Iyer R, Soliman P, Frumovitz M, Kundra V.

J Magn Reson Imaging. 2017 Apr;45(4):1216-1224. doi: 10.1002/jmri.25427. Epub 2016 Aug 17.

PMID:
27532860
40.

Corrigendum to "Sequencing of mutational hotspots in cancer-related genes in small cell neuroendocrine cervical cancer" [Gynecol. Oncol. 141 (2016) 588-591].

Frumovitz M, Burzawa JK, Byers LA, Lyons YA, Ramalingam P, Coleman RL, Brown J.

Gynecol Oncol. 2016 Oct;143(1):224. doi: 10.1016/j.ygyno.2016.07.108. Epub 2016 Jul 28. No abstract available.

41.

Role of cervical cytology in surveillance after radical trachelectomy for cervical cancer.

Brown AJ, Shah JS, Fleming ND, Nick AM, Soliman PT, Chisholm GB, Schmeler KM, Ramirez PT, Frumovitz M.

Gynecol Oncol. 2016 Aug;142(2):283-5. doi: 10.1016/j.ygyno.2016.05.030. Epub 2016 Jun 6.

42.

Sequencing of mutational hotspots in cancer-related genes in small cell neuroendocrine cervical cancer.

Frumovitz M, Burzawa JK, Byers LA, Lyons YA, Ramalingam P, Coleman RL, Brown J.

Gynecol Oncol. 2016 Jun;141(3):588-591. doi: 10.1016/j.ygyno.2016.04.001. Epub 2016 Apr 15. Erratum in: Gynecol Oncol. 2016 Oct;143(1):224.

43.

Is MRI helpful in assessing the distance of the tumour from the internal os in patients with cervical cancer below FIGO Stage IB2?

Bhosale PR, Iyer RB, Ramalingam P, Schmeler KM, Wei W, Bassett RL, Ramirez PT, Frumovitz M.

Clin Radiol. 2016 Jun;71(6):515-22. doi: 10.1016/j.crad.2016.02.009. Epub 2016 Mar 21.

44.

Small- and Large-Cell Neuroendocrine Cervical Cancer.

Frumovitz M.

Oncology (Williston Park). 2016 Jan;30(1):70, 77-8, 93. Review. No abstract available.

45.

An Open Letter to the Food and Drug Administration Regarding the Use of Morcellation Procedures in Women Having Surgery for Presumed Uterine Myomas.

Parker W, Berek JS, Pritts E, Olive D, Kaunitz AM, Chalas E, Clarke-Pearson D, Goff B, Bristow R, Taylor HS, Farias-Eisner R, Fader AN, Maxwell GL, Goodwin SC, Love S, Gibbons WE, Foshag LJ, Leppert PC, Norsigian J, Nager CW, Johnson T, Guzick DS, As-Sanie S, Paulson RJ, Farquhar C, Bradley L, Scheib SA, Bilchik AJ, Rice LW, Dionne C, Jacoby A, Ascher-Walsh C, Kilpatrick SJ, Adamson GD, Siedhoff M, Israel R, Paraiso MF, Frumovitz MM, Lurain JR, Al-Hendy A, Benrubi GI, Raman SS, Kho RM, Anderson TL, Reynolds RK, DeLancey J.

J Minim Invasive Gynecol. 2016 Mar-Apr;23(3):303-8. doi: 10.1016/j.jmig.2015.12.012. Epub 2016 Jan 8. No abstract available.

PMID:
26773577
46.

Role of Indocyanine Green in Sentinel Node Mapping in Gynecologic Cancer: Is Fluorescence Imaging the New Standard?

Darin MC, Gómez-Hidalgo NR, Westin SN, Soliman PT, Escobar PF, Frumovitz M, Ramirez PT.

J Minim Invasive Gynecol. 2016 Feb 1;23(2):186-93. doi: 10.1016/j.jmig.2015.10.011. Epub 2015 Oct 28. Review.

PMID:
26518716
47.

Impact of Lymph Node Ratio and Adjuvant Therapy in Node-Positive Endometrioid Endometrial Cancer.

Fleming ND, Soliman PT, Westin SN, dos Reis R, Munsell M, Klopp AH, Frumovitz M, Nick AM, Schmeler K, Ramirez PT.

Int J Gynecol Cancer. 2015 Oct;25(8):1437-44. doi: 10.1097/IGC.0000000000000510.

48.

Survivors of gynecologic malignancies: impact of treatment on health and well-being.

Westin SN, Sun CC, Tung CS, Lacour RA, Meyer LA, Urbauer DL, Frumovitz MM, Lu KH, Bodurka DC.

J Cancer Surviv. 2016 Apr;10(2):261-70. doi: 10.1007/s11764-015-0472-9. Epub 2015 Aug 6.

49.

Feasibility of a reduced field-of-view diffusion-weighted (rFOV) sequence in assessment of myometrial invasion in patients with clinical FIGO stage I endometrial cancer.

Bhosale P, Ma J, Iyer R, Ramalingam P, Wei W, Soliman P, Frumovitz M, Kundra V.

J Magn Reson Imaging. 2016 Feb;43(2):316-24. doi: 10.1002/jmri.25001. Epub 2015 Jul 16.

50.

Is it equivalent? Evaluation of the clinical activity of single agent Lipodox® compared to single agent Doxil® in ovarian cancer treatment.

Smith JA, Costales AB, Jaffari M, Urbauer DL, Frumovitz M, Kutac CK, Tran H, Coleman RL.

J Oncol Pharm Pract. 2016 Aug;22(4):599-604. doi: 10.1177/1078155215594415. Epub 2015 Jul 15.

PMID:
26183293

Supplemental Content

Loading ...
Support Center